saralasin [7065]
saralasin
| SMILES | CNCC(=O)NC(CCCN=C(N)N)C(=O)NC(C(=O)NC(Cc1ccc(O)cc1)C(=O)NC(C(=O)NC(Cc1cnc[nH]1)C(=O)N1CCCC1C(=O)NC(C)C(=O)O)C(C)C)C(C)C |
| InChIKey | PFGWGEPQIUAZME-UHFFFAOYSA-N |
| Sequence | XRVYVHPA |
| HELM | PEPTIDE1{[Sar].(R,[dR]).(V,[dV]).(Y,[dY]).(V,[dV]).(H,[dH]).(P,[dP]).(A,[dA])}$$$$V2.0 |
Chemical Properties
| Hydrogen bond acceptors | 12 |
| Hydrogen bond donors | 12 |
| Rotatable bonds | 25 |
| Log P | -2.510 |
| Molecular weight (Da) | 911.5 |
| Stereochemistry info | unspecified |
Database connections
Bioactivities
| Receptor | Activity | Source | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Protein | Gene | Species | Family | Class | Type | Min | Avg | Max | Database |
| Receptor | Activity | Source | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Protein | Gene | Species | Family | Class | Type | Min | Avg | Max | Database |
saralasin
Drug properties
| Molecular type | Peptide |
| Physiological/Surrogate | Surrogate |
| Approved drug | Yes |
Distribution across phases (no. indications)
Phase I
0
Phase II
0
Phase III
0
Phase IV
0